Subject:PLN 10.8 million in sales revenue (+55% YoY) and positive EBITDA -selected estimated financial data of the Medicalgorithmics Capital Groupfor Q2 2026

CurrentReport No.:30/2026Date of preparation:9 July 2026Legal basis:Article 17(1) of the MAR Regulation - inside information

MedicalgorithmicsS.A., with its registered office in Warsaw (the "Company", the"Issuer"), hereby announces that in the second quarter of 2026, theestimated, unaudited consolidated sales revenue of the MedicalgorithmicsCapital Group amounted to a total of PLN 10,795 thousand, including PLN4,744 thousand generated in the U.S. market, while the number ofsessions, i.e. ECG analyses performed using the Company's systemsreached 118 174 sessions. Thepreliminary estimated EBITDA (operating result increased by depreciationand amortization) for this period amounted to PLN 1,245 thousand.

For comparison,in the second quarter of the previous calendar year, these figures wereas follows: sales revenue of PLN 6,969 thousand, including PLN 2,250thousand in the U.S. market; the number of sessions reached 96 526;EBITDA for that period was negative and amounted to PLN -953 thousand.

The ManagementBoard emphasizes that this report contains estimated data that will besubject to auditor's review and may change as a result of furtherfinancial reporting procedures. Final information regarding theconsolidated sales revenue achieved in Q2 2026, including in the U.S.market, the number of sessions completed by the Company in this period,and EBITDA will be presented in the interim condensed consolidatedfinancial statements of the Medicalgorithmics Capital Group for H1 2026.

The ManagementBoard also announces that it has decided to publish similar estimateddata immediately after the end of each subsequent quarter - as soon assuch data is prepared, but no later than by the middle of the monthfollowing the end of the given calendar quarter.